FluoGuide is trading 6.76% up at SEK 37.90 after continued investor reaction to its August 25, 2026 interim report.

  • The report highlighted FDA approval for the first U.S. high-grade glioma trial site and Fast Track designation.
  • Progress continued toward activating seven additional sites.
  • No newer company announcement dated September 2 was identified; broader markets were mixed to weaker, making macro sentiment an unlikely primary driver.